Amneal Pharmaceuticals develops, manufactures and commercializes generic and specialty medicines, with a broad U.S. generics portfolio plus select branded, injectable and biosimilar-related products. It operates manufacturing and R&D capacity aimed at complex dosage forms as well as high-volume oral solids. Customers include wholesalers, pharmacies, hospitals and other channels that supply affordable prescription alternatives.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 724.5 | — | 22.4 | — |
| Q3 2025 | 784.5 | — | 2.4 | — |
| Q4 2025 | 814.3 | — | 35.1 | — |
| Q1 2026 | 722.5 | — | 62.3 | — |
| Q2 2026 | 796.2 | 9.9% | 57.7 | 157.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Cogent Biosciences, Inc. (COGT), Caesars Entertainment, Inc. (CZR), Pegasystems Inc. (PEGA), Open Text Corporation (OTEX), Construction Partners, Inc. (ROAD), Hamilton Lane Incorporated (HLNE)